v3.26.1
Earnings (Loss) Per Share (Tables)
 6 Months Ended
Jun. 30, 2026
Earnings Per Share [Abstract]  
Schedule of calculation of basic and diluted earnings (loss) per share
Computations of basic and diluted net income (loss) per share from continuing operations and discontinued operations were as follows (in thousands, except per share data):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Numerator
Net (loss) income from continuing operations$(144,106)$5,381 $(167,956)$(7,121)
Less: Income attributable to noncontrolling interest1,210 1,154 2,377 2,282 
Net (loss) income from continuing operations attributable to AdaptHealth Corp.(145,316)4,227 (170,333)(9,403)
Less: Earnings allocated to participating securities (1)
— 356 — (792)
Net (loss) income from continuing operations for basic and diluted EPS$(145,316)$3,871 $(170,333)$(8,611)
Net income from discontinued operations$11,387 $10,447 $20,364 $16,870 
Less: Earnings allocated to participating securities (1)
— 879 — 1,421 
Net income from discontinued operations for basic and diluted EPS$11,387 $9,568 $20,364 $15,449 
Denominator
Basic weighted-average common shares outstanding136,120134,993135,950134,897
Add: Stock options (2)
—169——
Add: Unvested restricted stock units (2)
—1,909——
Diluted weighted-average common shares outstanding136,120137,071135,950134,897
Basic net income (loss) per share:
Continuing operations$(1.07)$0.03 $(1.25)$(0.06)
Discontinued operations0.08 0.07 0.15 0.11 
Net income (loss) per share$(0.99)$0.10 $(1.10)$0.05 
Diluted net income (loss) per share:
Continuing operations$(1.07)$0.03 $(1.25)$(0.06)
Discontinued operations0.08 0.07 0.15 0.11 
Net income (loss) per share$(0.99)$0.10 $(1.10)$0.05 
(1)The Company’s preferred stock are considered participating securities. Computation of EPS under the two-class method excludes from the numerator any dividends paid or owed on participating securities and any undistributed earnings considered to be attributable to participating securities. The related participating securities are similarly excluded from the denominator. There were no amounts allocated to the participating securities during the three and six months ended June 30, 2026 due to the consolidated net loss reported in those periods.
(2)Due to the Company reporting net loss from continuing operations attributable to AdaptHealth Corp. for the three and six months ended June 30, 2026 and the six months ended June 30, 2025, all potentially dilutive securities related to outstanding stock options and unvested restricted stock units were excluded from the computation of diluted net loss per share for those periods as their inclusion would have been anti-dilutive.
Schedule of antidilutive securities excluded from computation of earnings per share
The table below provides the weighted-average number of potential common shares associated with outstanding securities not included in the Company’s computation of diluted net income (loss) per share for continuing operations and discontinued operations for the three and six months ended June 30, 2026 and 2025 because to do so would be anti-dilutive (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Preferred Stock12,40612,40612,40612,406
Stock options7669847661,153
Unvested restricted stock units4,9372,4974,9374,406
Total18,10915,88718,10917,965